Abstract: The invention relates to a solid dispersion comprising Coenzyme Q10 and a phospholipid, in the presence of a cellulosic derivative and/or a polymeric material selected from the group consisting of polyvinylpyrrolidone, polyvinyl acetate, poly (methacrylic acid, methyl methacrylate), poloxamers, chitosan, alginates, hyaluronic acid, pectin, pullulan, cyclodextrins, starch polymers, D-alpha-tocopheryl polyethylene glycol 1000 succinate.
Abstract: The present invention relates to various topical veterinary compositions comprising fipronil, an insect growth regulator, and a veterinarily acceptable carrier.
Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
Type:
Grant
Filed:
February 15, 2019
Date of Patent:
January 5, 2021
Assignee:
Nektar Therapeutics
Inventors:
Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Abstract: The present invention relates to compositions and kits including a chemical uncoupler, such as tyrphostin 9 or precursor or a salt thereof, and compositions including a chemical uncoupler, such as tyrphostin 9 in combination with one or more therapeutic agents, for example, L-carnitine, which are useful, for example, in treating obesity, preventing weight gain, promoting weight loss/slimming, and/or treating or preventing the development of diabetes.
Type:
Grant
Filed:
July 2, 2015
Date of Patent:
December 1, 2020
Assignee:
NAN Global, LLC
Inventors:
Gabriel Gojon-Zorrilla, Gabriel Gojon-Romanillos
Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imizazo-fused heterocycle compounds useful to treat leukemia and other hematopoietic disorders.
Abstract: The present invention relates to sobrerol or a pharmaceutically acceptable salt thereof, which can promote differentiation of myoblasts to form myotubes, thereby preventing muscle weakness and effectively improving muscle functions. Therefore, the pharmaceutical composition containing the same can be effectively used for preventing or treating muscle weakness related diseases.
Type:
Grant
Filed:
September 9, 2016
Date of Patent:
September 8, 2020
Assignees:
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Ki Sun Kwon, Jeongi Choi, Sung Sup Park, Sun Gun Chung, Eun Soo Kwon, Kwang-Pyo Lee, Seung Min Lee
Abstract: The present invention relates generally to the field of flavan-3-ols. In particular, the present invention provides a way to increase the bioavailability of flavan-3-ols. Embodiments of the present invention relate to the use of at least one polyphenolic compound in a composition comprising at least one flavan-3-ol for increasing the bioavailability of said flavan-3-ol, wherein the at least one polyphenolic compound is selected from a group consisting of flavonols, flavones, isoflavones, flavanones, or combinations thereof.
Type:
Grant
Filed:
November 29, 2013
Date of Patent:
July 28, 2020
Assignee:
Societe des Produits Nestle S.A.
Inventors:
Lucas Actis Goretta, Antoine Leveques, Marcia Da Silva Pinto, Magalie Sabatier, Maarit Rein, Gary Williamson, Fabiola Dionisi
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Abstract: Provided herein are compositions comprising a stable water-in-silicone emulsion, and methods and kits comprising the compositions for treating conditions.
Abstract: The purpose of the present invention is to provide a polymer gel that can increase drug content ratio and reduce undesirable influence on gel strength and shape stability after the drug release, compared with the conventional techniques. The purpose can be achieved by an anionic drug-containing medical device comprising: (1) an anionic drug; and (2) a copolymer which contains, as constituents, a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and a monomer capable of copolymerizing with the condensation product or the salt of the condensation product.
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
May 26, 2020
Assignee:
Enzo Biochem, Inc.
Inventors:
Elazar Rabbani, James J. Donegan, Paul Diamond
Abstract: The invention relates to the field of metal-organic framework materials and the field of medical technology, relates to a method for inhibiting tumor angiogenesis or preventing and/or treating tumor, comprising administering to a subject in need thereof an effective amount of a metal-organic framework comprising Fe and ligand. The invention further relates to a method for inhibiting the expression of matrix metalloproteinase in a cell, comprising administering to the cell an effective amount of a metal-organic framework comprising Fe and ligand.
Type:
Grant
Filed:
May 8, 2017
Date of Patent:
May 19, 2020
Assignee:
Yunnan University
Inventors:
Bin Li, Daomei Chen, Jiaqiang Wang, Minfang Nie
Abstract: This invention concerns a cosmetic composition comprising, in a physiologically acceptable medium, an aqueous phase, spiculisporic acid and/or one of its salts, and at least one ester of fatty acid and optionally polyoxyalkylenated (poly)glycerol. This invention further concerns the non-therapeutic, cosmetic use of the cosmetic composition as a hygienic product, makeup, a cleaning product, and/or care product of the skin and/or hair.
Abstract: Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.
Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
Type:
Grant
Filed:
January 31, 2019
Date of Patent:
April 21, 2020
Assignee:
Wex Medical Limited
Inventors:
Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
Abstract: Provided are novel biocompatible copolymers, compositions comprising the copolymers, and methods of using the copolymers. The copolymers are non-toxic and typically have an LCST below 37° C. Compositions comprising the copolymers can be used for wound treatment, as a cellular growth matrix or niche and for injection into cardiac tissue to repair and mechanically support damaged tissue. The copolymers comprise numerous ester linkages so that the copolymers are erodeable in situ. Degradation products of the copolymers are soluble and non-toxic. The copolymers can be amine-reactive so that they can conjugate with proteins, such as collagen. Active ingredients, such as drugs, can be incorporated into compositions comprising the copolymers.
Type:
Grant
Filed:
April 14, 2015
Date of Patent:
March 17, 2020
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Hongbin Jiang, William R. Wagner, Tomo Yoshizumi, Yang Zhu
Abstract: A kit that is made of an apparatus comprising a bottle and a nozzle sprayer, and a pharmaceutical formulation comprising dyclonine HCL, triamcinolone, dicyclomine, and dental powder. A method for treating mouth ulcers comprising administering to a patient a formulation comprising dyclonine HCL, triamcinolone, dicyclomine, and dental powder to an affected area.
Abstract: Described herein are inventions directed to methods of treating a diastolic cardiac dysfunction and the symptoms thereof in a subject that includes administering an amount of a TRPV2 receptor agonist effective to treat the diastolic cardiac dysfunction. The TRPV2 receptor agonist may be administered in at least one of an injection, orally, or transdermally. The amount of TRPV2 receptor agonist is sufficient to result in an improved performance on quantitative diagnostic criteria. In an embodiment, the TRPV2 receptor agonist is administered over a period of about 8 hours to about 24 hours. The TRPV2 receptor agonist may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years. Exemplary TRPV2 receptor agonists include probenecid, 2-aminoethoxydiphenyl borate, cannabinol, cannabidiol, and combinations thereof.
Abstract: A temozolomide compound according to formula (I) is described, wherein R1, L1, and X are defined herein. The temozolomide compound can be used to prepare polymers comprising temozolomide. Additionally, the polymers comprising temozolomide can be particularly useful in the treatment of certain diseases.
Type:
Grant
Filed:
September 20, 2017
Date of Patent:
February 18, 2020
Assignee:
THE UNIVERSITY OF MASSACHUSETTS
Inventors:
Todd Emrick, Matthew Skinner, Sarah M. Ward, Banishree Saha